BICYCLE THERAPEUTICS PLC-ADR (BCYC) Stock Price, Quote, News and Overview
NASDAQ:BCYC - Nasdaq - US0887861088 - ADR - Currency: USD
BCYC Quote, Performance and Key Statistics
10.23
-0.42 (-3.94%)
The current stock price of BCYC is 10.23 USD. In the past month the price decreased by -18.87%. In the past year, price decreased by -59.64%.
BCYC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About BCYC
Company Profile
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 284 full-time employees. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
Company Info
BICYCLE THERAPEUTICS PLC-ADR
Blocks A & B, Portway Building, Granta Park, Great Abington
Cambridge CAMBRIDGESHIRE CB22 3AT GB
CEO: Kevin Lee
Employees: 284
Company Website: https://www.bicycletherapeutics.com/
Investor Relations: https://investors.bicycletherapeutics.com/
Phone: 11441223261503
BICYCLE THERAPEUTICS PLC-ADR / BCYC FAQ
What is the stock price of BICYCLE THERAPEUTICS PLC-ADR today?
The current stock price of BCYC is 10.23 USD. The price decreased by -3.94% in the last trading session.
What is the ticker symbol for BICYCLE THERAPEUTICS PLC-ADR stock?
The exchange symbol of BICYCLE THERAPEUTICS PLC-ADR is BCYC and it is listed on the Nasdaq exchange.
On which exchange is BCYC stock listed?
BCYC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BICYCLE THERAPEUTICS PLC-ADR stock?
20 analysts have analysed BCYC and the average price target is 30.18 USD. This implies a price increase of 194.97% is expected in the next year compared to the current price of 10.23. Check the BICYCLE THERAPEUTICS PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BICYCLE THERAPEUTICS PLC-ADR worth?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) has a market capitalization of 707.94M USD. This makes BCYC a Small Cap stock.
How many employees does BICYCLE THERAPEUTICS PLC-ADR have?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) currently has 284 employees.
What are the support and resistance levels for BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) has a resistance level at 10.96. Check the full technical report for a detailed analysis of BCYC support and resistance levels.
Is BICYCLE THERAPEUTICS PLC-ADR (BCYC) expected to grow?
The Revenue of BICYCLE THERAPEUTICS PLC-ADR (BCYC) is expected to decline by -16.27% in the next year. Check the estimates tab for more information on the BCYC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BCYC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BCYC, evaluating the profitability, health, valuation and growth aspects
- BICYCLE THERAPEUTICS PLC-ADR (BCYC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BICYCLE THERAPEUTICS PLC-ADR (BCYC) Sales and EPS estimates to see what analysts future expectations are.
- BICYCLE THERAPEUTICS PLC-ADR (BCYC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BICYCLE THERAPEUTICS PLC-ADR (BCYC) Insider and Institutional Ownership to learn about the owners and their transactions.
- BICYCLE THERAPEUTICS PLC-ADR (BCYC) Stock Chart to make your own analysis
- BICYCLE THERAPEUTICS PLC-ADR (BCYC) Latest news and press-releases to stay up to date.
Does BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock pay dividends?
BCYC does not pay a dividend.
When does BICYCLE THERAPEUTICS PLC-ADR (BCYC) report earnings?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) will report earnings on 2025-04-30, before the market open.
What is the Price/Earnings (PE) ratio of BICYCLE THERAPEUTICS PLC-ADR (BCYC)?
BICYCLE THERAPEUTICS PLC-ADR (BCYC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.95).
What is the Short Interest ratio of BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock?
The outstanding short interest for BICYCLE THERAPEUTICS PLC-ADR (BCYC) is 9.2% of its float. Check the ownership tab for more information on the BCYC short interest.
BCYC Technical Analysis
BCYC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BCYC. While BCYC has a great health rating, there are worries on its profitability.
BCYC Financial Highlights
Over the last trailing twelve months BCYC reported a non-GAAP Earnings per Share(EPS) of -2.95. The EPS increased by 42.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.67% | ||
| ROE | -21.31% | ||
| Debt/Equity | 0 |
BCYC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to BCYC. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of -22.92% and a revenue growth -16.27% for BCYC